Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies
Theranostics For Oncology Push
As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.
You may also be interested in...
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023
Amid upheaval for leading industry players Sandoz, Teva and Viatris, Amneal sees room to grow both in its home market and internationally, according to co-CEO Chirag Patel.
Scrip reporters spoke with many biopharma industry execs and observers during the J.P. Morgan Healthcare Conference in San Francisco – here are some of the highlights from interviews and presentations.